Abecma May Be Effective Early Therapy for Hard-to-treat Myeloma
Note: This story was updated Sept. 26, 2022, to correct the fact that Abecma is approved for patients in Europe and Japan who have undergone at least three prior therapies, not four as originally stated. The CAR T-cell therapy Abecma (idecabtagene vicleucel) significantly extended survival without signs of disease worsening…